A clinicopathologic and immunohistochemical study of primary and secondary breast angiosarcoma

Evi Abada; 장혜정; 김성호; Rouba Ali-Fehmi; Sudeshna Bandyopadhyay

doi:10.4132/jptm.2022.08.31

추천

검색

자료유형: 학술저널

저자정보: Evi Abada (Wayne State University School of Medicine) 장혜정 (Wayne State University School of Medicine) 김성호 (Wayne State University School of Medicine) Rouba Ali-Fehmi (Wayne State University School of Medicine) Sudeshna Bandyopadhyay (Wayne State University School of Medicine)

저널정보: 대한병리학회 Journal of Pathology and Translational Medicine Journal of Pathology and Translational Medicine 제56권 제6호

발행연도: 2022.11

수록면: 342 - 353 (12page)

DOI: 10.4132/jptm.2022.08.31

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: We aimed to study the clinicopathologic and immunohistochemical (IHC) (CD117, c-Myc, and p53) characteristics, and overall survival of primary and secondary breast angiosarcoma (BAS). Methods: This was a retrospective study of BAS cases diagnosed between 1997 and 2020 at our institution. Hematoxylin and eosin-stained slides were reviewed for tumor morphology, margin status, and lymph node metastasis. CD117, p53, D2-40, CD31, and c-Myc IHC stains were performed on 11 viable tissue blocks. Additional clinical information was obtained from the electronic medical records. Results: Seventeen patients with BAS were identified. Of these, five (29%) were primary and 12 (71%) were secondary BAS, respectively. The median age at diagnosis for primary BAS was 36 years. The median age at diagnosis for secondary BAS was 67 years. The median time to secondary BAS development following radiotherapy was 6.5 years (range, 2 to 12 years). There was no significant difference between primary and secondary BAS in several histopathologic parameters examined, including histologic grade, necrosis, mitotic count, lymph node metastasis, and positive tumor margins. There was also no difference in CD117, p53, D2-40, CD31, and c-Myc expression by IHC between primary and secondary BAS. During a median followup of 21 months, primary BAS had two (40%) reported deaths and secondary BAS had three (25%) reported deaths. However, this difference in survival between both groups was not statistically significant (hazard ratio, 0.51; 95% confidence interval, 0.09 to 3.28; p = .450). Conclusions: BAS is a rare and aggressive disease. No histologic, IHC (CD117, c-Myc, and p53), or survival differences were identified between primary and secondary BAS in this study.

#Breast angiosarcoma #Primary breast angiosarcoma #Secondary breast angiosarcoma #Immunohistochemistry #Overall survival

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!